← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Alpha glucosidase inhibitors
voglibose
A10BF03
Forms & Strengths
- Oral tablet: 0.2 mg
- Oral tablet: 0.3 mg
Adult Dosing
- 0.2 mg orally three times daily immediately before each meal
- May be increased to 0.3 mg orally three times daily if effect is insufficient
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Improvement of postprandial hyperglycemia in patients with type 2 diabetes mellitus
Mechanism of Action
- Alpha-glucosidase inhibitor that competitively inhibits alpha-glucosidase enzymes in the small intestine
- Delays the digestion and absorption of disaccharides and complex carbohydrates
- Reduces postprandial blood glucose spikes
Contraindications
- Hypersensitivity to voglibose or other alpha-glucosidase inhibitors
- Severe ketosis, diabetic coma, or pre-coma
- Severe infection, pre- or post-surgery, or severe trauma
- Severe hepatic or renal impairment
- History of bowel obstruction or inflammatory bowel disease
Adverse Reactions
- Flatulence
- Abdominal distension
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Elevated liver enzymes
- Hypoglycemia (when used with other antidiabetic agents)
Drug Interactions
- Enhanced hypoglycemic effects when combined with insulin or sulfonylureas
- Effectiveness decreased by sympathomimetics, corticosteroids, and thyroid hormones
- Absorbed concomitantly administered digoxin or ranitidine bioavailability may be altered
Curated Content: Needs Vetting Before Put to Clinical Use